Paclitaxel in combination with weekly 24-hour infusional 5-fluorouracil plus leucovorin in the second-line treatment of metastatic breast cancer: results of a phase II study
| Autor: | U. Klaassen, K. Neumann, C. Philippou Pari, Wolf Achterrath, Dirk Strumberg, Wilfried Eberhardt, Hansjochen Wilke, L. Lenaz, Andreas Harstrick, Siegfried Seeber |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
Adult
medicine.medical_specialty Anthracycline Paclitaxel Nausea medicine.medical_treatment Leucovorin Phases of clinical research Breast Neoplasms Neutropenia Gastroenterology Drug Administration Schedule Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Infusions Intravenous Aged Salvage Therapy Chemotherapy business.industry Hematology Middle Aged medicine.disease Metastatic breast cancer Surgery Treatment Outcome Oncology Fluorouracil Female medicine.symptom business Progressive disease medicine.drug |
| Zdroj: | Annals of oncology : official journal of the European Society for Medical Oncology. 9(1) |
| ISSN: | 0923-7534 |
| Popis: | Summary Purpose To evaluate the antitumor activity in terms of response rate (RR), time to progression (TTP) and survival of paclitaxel in combination with weekly 24-hour infusional 5-fluorouracil (5-FU)/leucovorin in pretreated metastatic breast cancer (MBC). Patients and methods Fifty-four patients with bidimensionally measureable disease were included during phase II. Thirty-two had anthracycline resistant disease. Treatment consisted of 5-FU (24-hour i.v. infusion) 2.0 g/m2, leucovorin (two-hour i.v. infusion prior to 5-FU) 500 mg/m2, weekly for six weeks (day 1, 8, 15, 22, 29, 36) and paclitaxel (three-hour i.v. infusion) 175 mg/m2 was administered additionally on days 1 and 22, q 50 days. Results We observed complete remissions in 4% of patients (2 of 54), partial remissions in 55% (30 of 54), stable disease in 37% (20 of 54) and progressive disease in 4% (2 of 54). The overall RR was 59% (95% CI 48%–72%). The RR in 32 patients with anthracycline resistant disease was 59% (19 of 32). The median duration of response was 12 months 3–22, median TTP eight months (2–22) and median survival time 15 months (2–28). Neutropenia was common, but of CTC grade 2 or 3 in most patients. Nonhematologic toxicities mostly consisted of CTC grade 1 and 2 myalgia, diarrhea, mucosits, nausea and vomiting. Conclusions Paclitaxel combined with weekly 24-hour infusional 5-FU/leucovorin is well tolerated in the second line treatment of MBC. High efficacy was documented even in the treatment of anthracycline resistant disease, which warrants further evaluation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|